A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy

A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy

Osimertinib contributes to the higher efficacy and few intestinal side effects in non-small cell lung cancer (NSCLC) patients with T790M mutation. Previous studies has reported that intestinal microbiota play important roles in drug efficacy and toxicity. However, we have known less about the change...

Full description

Bibliographic Details
Main Authors: Jing Cong, Yuguang Zhang, Yadong Xue, Chuantao Zhang, Mingjin Xu, Dong Liu, Ruiyan Zhang, Hua Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Microbiology
Subjects:
intestinal microbiota
16S rRNA sequencing
non-small cell lung cancer patients
osimertinib therapy
ecological network analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2020.583525/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2020.583525/full

Similar Items